This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Histone deacetylase 1 (HDAC1); HDAC2	<p>A study in mice and in cell culture suggests that simultaneous inhibition of HDAC1 and HDAC2 could be useful for treating cancer. In tumor cell lines, knocking out both HDAC1 and HDAC2 lowered cell viability and proliferation compared with what was seen in single knockouts. In mice, inoculation with tumor cells lacking Hdac1 and Hdac2 prevented tumor formation compared with that seen in controls. Next steps could include developing dual inhibitors specific to HDAC1 and HDAC2 and testing them <i>in vivo</i>.</p> <p>Zolinza vorinostat, an HDAC inhibitor from Merck & Co. Inc., is marketed to treat cutaneous T cell lymphoma (CTCL).</p> <p>Belinostat, a small molecule HDAC inhibitor from TopoTarget A/S, is in Phase III testing to treat T cell lymphoma.</p> <p>At least 15 other companies have HDAC inhibitors in Phase II or earlier development for various cancers.</p> <p>SciBX 2(19); doi:10.1038/scibx.2009.780 Published online May 14, 2009</p>	Patent and licensing status unavailable	<p>Haberland, M. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online April 27, 2009; doi:10.1073/pnas.0903139106</p> <p>Contact: Eric N. Olson, University of Texas Southwestern Medical Center, Dallas, Texas e-mail: eric.olson@utsouthwestern.edu</p>